ReviewJournal of translational medicine2026
Single-cell T-cell landscape in atherosclerosis: implications for targeted therapy and beyond.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting the Th17/Treg axis: from immunological insights to therapeutic avenues in atherosclerosis.Frontiers in immunology · 2026Review
- Type 2 diabetes mellitus and incident carotid atherosclerosis: a retrospective cohort study on composite indices.Frontiers in endocrinology · 2026Article
- Inflammatory drivers of carotid atherosclerosis: signaling pathways, immune cells, and plaque stability.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtherosclerosis (AS) progression is profoundly influenced by dynamic T-cell heterogeneity and functional plasticity. MAIN BODY: This review consolidates the latest insights derived from single-cell transcriptomic technologies, which are transforming our understanding of the role of the immune system in plaque pathogenesis. Recent evidence revealed previously unrecognized T-cell subsets within murine and human atherosclerotic lesions, distinguished by unique transcriptional profiles and adaptability driven by their microenvironment. Spatial mapping techniques have revealed compartment-specific distributions of T cells across vascular layers, whereas temporal analyses have highlighted age-related changes in the balance between effector and regulatory functions. Notably, single-cell resolution delineated transitional states between cytotoxic and regulatory lineages, suggesting that local inflammatory signals play a crucial role in determining T-cell fate. Despite these advancements, challenges remain in fully understanding T-cell lineage commitment, plasticity, and interactions with vascular niches. The integration of emerging multiomics approaches and spatial transcriptomics holds promise for addressing these challenges, providing a roadmap for novel therapeutic strategies. This includes not only the development of targeted immunotherapies but also the identification of key molecular targets for drug intervention and precision diagnostics, ultimately broadening the horizon for clinical applications in atherosclerosis.
conclusionsThis review synthesizes single-cell RNA sequencing-driven discoveries in AS immunology, highlighting the heterogeneity and plasticity of plaque T-cell subsets. These insights lay the groundwork for developing targeted immunotherapies and identifying novel molecular targets and diagnostic biomarkers, ultimately advancing precision medicine for AS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.